Go Pro
→ The ultimate IPO unicorn (From Weiss Ratings) (Ad)tc pixel Free RNAZ Stock Alerts

TransCode Therapeutics (RNAZ) Competitors

TransCode Therapeutics logo
$3.88 -0.08 (-2.02%)
As of 04:00 PM Eastern
Compare

RNAZ vs. NXTC, JSPR, APLT, OSRH, and HIND

Should you buy TransCode Therapeutics stock or one of its competitors? MarketBeat compares TransCode Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransCode Therapeutics include NextCure (NXTC), Jasper Therapeutics (JSPR), Applied Therapeutics (APLT), OSR (OSRH), and Vyome (HIND). These companies are all part of the "biotechnology" industry.

How does TransCode Therapeutics compare to NextCure?

NextCure (NASDAQ:NXTC) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

NextCure's return on equity of -154.62% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -154.62% -100.19%
TransCode Therapeutics N/A -875.35%-50.36%

NextCure has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

NextCure presently has a consensus target price of $19.00, indicating a potential upside of 177.78%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NextCure is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NextCure is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$8.70N/A
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A

42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NextCure had 6 more articles in the media than TransCode Therapeutics. MarketBeat recorded 7 mentions for NextCure and 1 mentions for TransCode Therapeutics. NextCure's average media sentiment score of 0.59 beat TransCode Therapeutics' score of 0.00 indicating that NextCure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NextCure
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TransCode Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

NextCure beats TransCode Therapeutics on 10 of the 13 factors compared between the two stocks.

How does TransCode Therapeutics compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Jasper Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A

Jasper Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for TransCode Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jasper Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TransCode Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

79.9% of Jasper Therapeutics shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jasper Therapeutics' return on equity of -613.51% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -613.51% -162.52%
TransCode Therapeutics N/A -875.35%-50.36%

Jasper Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 1,401.13%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Jasper Therapeutics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Jasper Therapeutics beats TransCode Therapeutics on 9 of the 12 factors compared between the two stocks.

How does TransCode Therapeutics compare to Applied Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

TransCode Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A

In the previous week, TransCode Therapeutics had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Applied Therapeutics. TransCode Therapeutics' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company Overall Sentiment
TransCode Therapeutics Neutral
Applied Therapeutics Neutral

Applied Therapeutics' return on equity of -340.84% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -50.36%
Applied Therapeutics N/A -340.84%-175.00%

98.3% of Applied Therapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TransCode Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Applied Therapeutics beats TransCode Therapeutics on 8 of the 12 factors compared between the two stocks.

How does TransCode Therapeutics compare to OSR?

OSR (NASDAQ:OSRH) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, OSR had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for OSR and 1 mentions for TransCode Therapeutics. OSR's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OSR
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TransCode Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

55.3% of OSR shares are held by institutional investors. 36.9% of OSR shares are held by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OSR has higher revenue and earnings than TransCode Therapeutics. OSR is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OSR$2.63M5.49-$27.06M-$0.33N/A
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A

TransCode Therapeutics has a net margin of 0.00% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OSR-363.26% -7.24% -5.41%
TransCode Therapeutics N/A -875.35%-50.36%

OSR has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OSR
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

OSR beats TransCode Therapeutics on 8 of the 11 factors compared between the two stocks.

How does TransCode Therapeutics compare to Vyome?

TransCode Therapeutics (NASDAQ:RNAZ) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Vyome has higher revenue and earnings than TransCode Therapeutics. Vyome is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A
Vyome$152.72K101.55-$10.26M-$12.27N/A

In the previous week, TransCode Therapeutics had 1 more articles in the media than Vyome. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Vyome. TransCode Therapeutics' average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.

Company Overall Sentiment
TransCode Therapeutics Neutral
Vyome Neutral

Vyome's return on equity of -203.92% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -50.36%
Vyome N/A -203.92%-134.16%

Vyome has a consensus price target of $15.00, suggesting a potential upside of 578.73%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Vyome
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

22.1% of Vyome shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 33.0% of Vyome shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TransCode Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Vyome has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Summary

Vyome beats TransCode Therapeutics on 10 of the 13 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAZ vs. The Competition

Export
MetricTransCode TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.11M$3.72B$7.06B$12.95B
Dividend YieldN/A3.76%2.58%10.20%
P/E Ratio-0.089.13269.7524.73
Price / SalesN/A1,274.20652.34108.63
Price / CashN/A44.9528.8937.44
Price / Book0.3417.6611.276.42
Net Income-$34.66M-$13.25M$3.45B$347.12M
7 Day Performance-8.06%5.36%3.56%2.48%
1 Month Performance-56.06%-1.74%-0.58%-1.04%
1 Year Performance-62.66%61.36%77.52%23.22%

TransCode Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAZ
TransCode Therapeutics
0.6656 of 5 stars		$3.88
-2.0%		N/A-61.9%$4.11MN/AN/A9
NXTC
NextCure
4.0106 of 5 stars		$5.13
-11.2%		$19.00
+270.4%		+19.9%$18.52MN/AN/A90
JSPR
Jasper Therapeutics
2.4843 of 5 stars		$0.64
-3.5%		$12.00
+1,767.7%		-71.0%$17.99MN/AN/A20
APLT
Applied Therapeutics
1.5236 of 5 stars		$0.10
flat		$1.00
+870.9%		N/A$15.86M$1MN/A30
OSRH
OSR
0.3734 of 5 stars		$0.45
-3.1%		N/A-26.6%$15.68M$2.91MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
$8B is moving in... are you?
Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...
Awesomely | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
Wall Street owns 88%. You don’t know the name.
Institutions already control 88% of this company's shares. BlackRock holds roughly 32 million shares, Vanguard...
Monument Traders Alliance | Sponsoredtc pixel
A $5 stock inside Kennedy Space Center?
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel